Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context

Soriano, Enrique R.; Galarza-Maldonado, Claudio; Cardiel, Mario H; Pons-Estel, Bernardo A.; Massardo, Loreto; Caballero-Uribe, Carlo V.; Achurra-Castillo, Ángel F.; Barile-Fabris, Leonor; Chavez-Corrales, Jose; Díaz-Coto, José Francisco; Esteva-Spinetti, María H; Guibert-Toledano, Marlene; Palazuelos, Fedra Irazoque; Keiserman, Mauro Waldemar; Lomonte, A. V.; Мота, Л.; Villaseñor, Carlos Pineda; Alarcón, Graciela S.

doi:10.1093/rheumatology/ken015a

Cited by 21 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EULAR 2011 vaccination guidelines 71 recommend that vaccination status should be assessed during the initial investigation of patients with RA, and 4 French biologic guidelines 27,28,29,33 recommended that clinicians should ensure that all indicated vaccines are up-to-date in patients with RA before starting biologic agents. Twelve guidelines recommended influenza and pneumococcal vaccine for all patients with RA 23,27,28,29,31,32,33,54,58,71,72 , and one guideline recommended these vaccines only for patients over age 65 years 24 . Five guidelines recommended immunization against hepatitis B if risk factors are present 31,32,58,60,61 and one guideline suggested that zoster vaccine could be considered in all patients with RA 71 .…”

Section: Recommendationmentioning

confidence: 99%

“…Two French guidelines recommended waiting at least 2 weeks before treatment with ABAT 28 or TCZ 27 . Five guidelines included recommendations for RTX 29,55,58,71,72 and all strongly suggested that vaccinations should be administered before initiating RTX, with 2 suggesting an interval of 4 weeks between vaccine administration and initiation of RTX therapy 29,72 . Recommendation/supporting evidence adapted from: EULAR 2011 71 (R*) and Canadian Immunization Guide 2006 70 .…”

Section: Rheumatologymentioning

confidence: 99%

See 1 more Smart Citation

Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety

Bombardier¹,

Hazlewood²,

Akhavan³

et al. 2012

J Rheumatol

125

147

View full text Add to dashboard Cite

ABSTRACT. Objective. The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part II, focusing on specific safety aspects of treatment with traditional and biologic DMARD in patients with RA, is reported here. Methods. Key questions were identified a priori based on results of a national needs-assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and was supplemented with a "grey literature" search including relevant public health guidelines. Systematic reviews of postmarketing surveillance and RA registry studies were performed to update included guideline literature reviews as appropriate. Guideline quality was independently assessed by 2 reviewers. Guideline characteristics, recommendations, and supporting evidence from observational studies and randomized trials were synthesized into evidence tables. The working group voted on recommendations using a modified Delphi technique.Results. Thirteen recommendations addressing perioperative care, screening for latent tuberculosis infection prior to the initiation of biologic DMARD, optimal vaccination practices, and treatment of RA patients with active or a history of malignancy were developed for rheumatologists, other primary prescribers of RA drug therapies, and RA patients. Conclusion. These recommendations were developed based on a synthesis of international RA and public health guidelines, supporting evidence, and expert consensus in the context of the Canadian health system. They are intended to help promote best practices and improve healthcare delivery for persons with RA. (First Release June 15 2012; J Rheumatol 2012;39:1583-602; doi:10.3899 Recommendations provided here are intended to be read in conjunction with the Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis. These recommendations address specific safety questions that were identified a priori and are not intended to cover all safety aspects concerning treatment with traditional and biologic disease modifying antirheumatic drugs (DMARD).Traditional and biologic DMARD have greatly enhanced the care of persons with rheumatoid arthritis (RA); however, potential risks associated with their use need be considered. The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of RA with traditional and biologic DMARD in 2 parts. Part I described the development process of CRA recommendations in detail and included 5 overarching RA care principles along with 26 treatment recommendations 1 . Part II, reported here, focuses on specific safety aspects of treatment with traditional and biologic DMARD in patients with ...

show abstract

Section: Recommendationmentioning

confidence: 99%

Section: Rheumatologymentioning

confidence: 99%

Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety

Bombardier¹,

Hazlewood²,

Akhavan³

et al. 2012

J Rheumatol

125

147

View full text Add to dashboard Cite

show abstract

“…9 The current guidelines provide evidencebased advice on the use of rituximab either alone or in combinations for physicians and rheumatologists to treat RA especially in patients with active [disease activity score 28 (DAS-28) ≥3.2] rheumatoid factor-positive RA who have had an incomplete response or intolerance to an adequate course with TNF inhibitors. 10 We applied rituximab to our case as a part of standard chemotherapy protocol, besides its effects on lymphoma, rituximab alleviated symptoms of RA in our case. At the end of chemotherapy regimen, our patient's symptoms related to RA were improved.…”

Section: Discussionmentioning

confidence: 72%

Diffuse Large B Cell Lymphoma Secondary to Rheumatoid Artritis: Case Report

Bilen¹,

Erdem²,

Gündoğdu³

et al. 2012

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

“…RTX may be used in patients with active RF-positive RA, who have had an incomplete response or intolerance to an adequate course with TNF- inhibitors and also can be used in patients with an inadequate response or intolerance to more than one conventional DMARD, who cannot receive TNF- inhibitors. RF-negative patients also can be considered for RTX treatment if they fulfill the treatment failure criteria 76 .…”

Section: Anti-cd20 Therapy In Ra Patients: Rituximabmentioning

confidence: 99%

Untitled

2011

IJPSR

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an aggressive disease that needs to be treated effectively if subsequent deformity and disability are to be reduced. A recent advance in the management of RA is the use of biological agents which block certain key molecules involved in the pathogenesis of the illness. They include tumor necrosis factor (TNF-) -blocking agents, Anti-Interleukin-1receptor (IL-1) antagonist, anti-CD-20 agents, CTLA-4 Ig, anti IL-6 etc. These newer agents proved to be useful for alleviating symptoms and slowing the disease progression in the patients with RA who have failed to respond to conventional disease modifying anti-rheumatic drugs (DMARDs). DMARDs are nonspecific immunomodulators, each of which has substantial drawbacks in terms of effectiveness or adverse effects (AEs). The development of biologic agents has provided more effective therapeutic options. The terms biologic therapies and biologics have emerged to describe agents with biologic properties, including monoclonal antibodies and soluble cytokine receptors etc. The advent of effective biological agents has certainly been a major advance in the treatment of inflammatory arthritis, heralding a new era for rheumatology. In this review the focus is only on pathophysiology of the disease process as well as the recent advances with Biological response modifiers (BRMs) and its impact on current clinical practice in the treatment of RA.

show abstract

Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context

Cited by 21 publications

References 8 publications

Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety

Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety

Diffuse Large B Cell Lymphoma Secondary to Rheumatoid Artritis: Case Report

Untitled

Contact Info

Product

Resources

About